HEALTHCARE
March 12, 2020
Patient Safety Movement Foundation (PSMF) – a global non-profit dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, and creating actionable solutions to mitigate them – is pleased to announce the appointment of its new chairman of the board of directors – Michael A.E. Ramsay, MD, FRCA. It also reaffirms its commitment to patient health and safety with updates to its mission, vision and values; and reestablishes its goal of achieving ZERO preventable patient deaths by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005733/en/......
March 12, 2020
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Regulatory News:
Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The company exceeded"...
Read More >>March 11, 2020
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients. The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival (PFS) of 13.5 months (35.3 months versus 21.8 months; hazard ratio [HR] 0.83; p=0.073); however, it did not meet the threshold for statistical significance. The safety profile associated with NINLARO from the TOURMALINE-MM2......
March 11, 2020
Sinterex named Best 3D-Printed Healthcare Products Manufacturer Middle East
Global Health & Pharma (GHP), a global information sharing platform & a multi-disciplinary members community announced winners of the 2019 Technology Awards this month and recognised Sinterex as Best 3D-Printed Healthcare Products Manufacturer – Middle East.
In"...
Read More >>March 9, 2020
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also studying whether Takeda’s currently marketed and pipeline products may be effective treatments for infected patients. SARS-CoV-2 is the virus that causes COVID-19. Hyperimmune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment......
March 8, 2020
National Center for Disease Control holds with WHO workshop on coronavirus
The National Center for Disease Control has held a training workshop for the rapid response teams with respect to the coronavirus outbreak.
The national-level workshop was organized by the monitoring, tracking"...
Read More >>March 8, 2020
Ministry of Health denies registration of any cases of coronavirus in Libya
The Libyan Ministry of Health of the Government of National Accord (GNA) confirmed that Libya is, to date, free from any cases of infection by coronavirus.
In an official statement, they denied all rumors regarding"...
Read More >>March 8, 2020
In observance of International Women’s Day, Fakih IVF Fertility Center is rolling out a special campaign supporting all women and their choices. The campaign is running throughout March, across the center’s branches located in Abu Dhabi, Dubai and Al Ain.
With"...
Read More >>March 7, 2020
– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients –
– Positive Opinion is Based on Data from Phase 3 ALTA-1L"...
Read More >>March 6, 2020
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for a total value in excess of $200 million USD. The divestment agreement was first announced in October 2019. The transaction includes approximately 30 select prescription pharmaceutical and OTC products. These products will continue to be made available by Takeda in other parts of the......
